89 terminated. 89 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 89 | Terminated 89 |
| Phase 2 | 9 | Terminated 9 |
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| Astaxanthin for Management of Inflammation in Knee Osteoarthritis Astaxanthin, Placebo - Osteoarthritis, Knee, Osteoarthritis Knees Both | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 16 | 2022-09-02 | 2025-05-20 |
| Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA TC99m-tilmanocept - Rheumatoid Arthritis | Phase 3 | Terminated | Navidea Biopharmaceuticals | 169 | 2022-03-02 | 2025-01-23 |
| 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis Lorecivivint - Osteoarthritis of the Knee | Phase 3 | Terminated | Biosplice Therapeutics, Inc. | 72 | 2021-07-15 | 2026-03-31 |
| Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 Colchicine 0.5 MG, CONTROL GROUP - Corona Virus Infection | Phase 3 | Terminated | Fundación Universitaria de Ciencias de la Salud | 128 | 2021-04-30 | 2022-02-23 |
| Adductor Canal Block Ropivacaine injection, Saline Injection, Total Knee Arthroplasty - Osteoarthritis, Total Knee Replacement | Phase 2 / Phase 3 | Terminated | OrthoCarolina Research Institute, Inc. | 93 | 2020-10-09 | 2026-04-06 |
| A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee Placebo, Lorecivivint - Osteoarthritis, Knee | Phase 3 | Terminated | Biosplice Therapeutics, Inc. | 276 | 2020-08-25 | 2026-03-24 |
| Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) Otilimab (GSK3196165), csDMARD(s) - Arthritis, Rheumatoid | Phase 3 | Terminated | GlaxoSmithKline | 2916 | 2020-05-12 | 2024-02-07 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy Filgotinib, Adalimumab, Placebo to match filgotinib - Psoriatic Arthritis | Phase 3 | Terminated | Gilead Sciences | 67 | 2019-12-03 | 2022-05-16 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy Filgotinib, Placebo to match filgotinib - Psoriatic Arthritis | Phase 3 | Terminated | Gilead Sciences | 106 | 2019-11-13 | 2022-03-18 |
| Symptomatic Management of Lyme Arthritis Naproxen, Acetaminophen - Lyme Arthritis, Lyme Disease | Phase 3 | Terminated | Desiree Neville, MD | 3 | 2019-10-01 | 2025-11-17 |
| Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. Ampion, Saline - Severe Osteoarthritis of the Knee | Phase 3 | Terminated | Ampio Pharmaceuticals. Inc. | 1043 | 2019-06-24 | 2022-10-05 |
| Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) GSK3196165 (Otilimab), Tofacitinib, Placebo - Arthritis, Rheumatoid | Phase 3 | Terminated | GlaxoSmithKline | 1764 | 2019-06-05 | 2023-11-30 |
| Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis FX006, Normal saline - Osteoarthritis, Hip | Phase 3 | Terminated | Pacira Pharmaceuticals, Inc | 70 | 2018-12-12 | 2024-01-24 |
| Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee 4 mL injection of AMPION™ - Severe Osteoarthritis of the Knee | Phase 3 | Terminated | Ampio Pharmaceuticals. Inc. | 94 | 2017-12-08 | 2022-10-03 |
| CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis CF101 1 mg, CF101 2 mg, Placebo - Rheumatoid Arthritis | Phase 3 | Terminated | Can-Fite BioPharma | 244 | 2017-10-30 | 2020-12-19 |
| Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee Fasinumab, Placebo - Chronic Low Back Pain, Osteoarthritis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 63 | 2017-10-30 | 2021-06-30 |
| A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD) anakinra, Placebo - Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset | Phase 3 | Terminated | Swedish Orphan Biovitrum | 13 | 2017-09-26 | 2021-06-30 |
| Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL) Multiprofen, Placebo - Knee Osteoarthritis | Phase 2 / Phase 3 | Terminated | University of Michigan | 50 | 2017-05-01 | 2019-03-20 |
Showing 20 of 89. Sign in to see all of them.
Arthritis, Rheumatoid (31) · Osteoarthritis (29) · Osteoarthritis, Knee (9) · Arthritis, Juvenile (8) · Arthritis, Psoriatic (6) · Pain (6) · Spondylitis, Ankylosing (5) · Gout (4) · Osteoarthritis, Hip (3) · Arthralgia (2) · Axial Spondyloarthritis (2) · Chronic Pain (2) · Collagen Diseases (2) · Hereditary Sensory and Autonomic Neuropathies (2)
Joint Diseases (88) · Musculoskeletal Diseases (88) · Rheumatic Diseases (76) · Skin and Connective Tissue Diseases (46) · Connective Tissue Diseases (40) · Autoimmune Diseases (38) · Immune System Diseases (38) · Pathological Conditions, Signs and Symptoms (15) · Bone Diseases (14) · Signs and Symptoms (11) · Spinal Diseases (11) · Spondylarthritis (11) · Spondylarthropathies (11) · Spondylitis (11)
Methotrexate (11) · tanezumab (7) · Buprenorphine (4) · golimumab (4) · ocrelizumab (4) · tabalumab (4) · tocilizumab (4) · Adalimumab (3) · Etanercept (3) · Leflunomide (3) · Allopurinol (2) · GLPG0634 (2) · Hyaluronic Acid (2) · Otilimab (2) · Saline Solution (2)
Pfizer (8) · Eli Lilly and Company (4) · Genentech, Inc. (4) · GlaxoSmithKline (4) · Hoffmann-La Roche (4) · Purdue Pharma LP (4) · Janssen Research & Development, LLC (3) · Novartis Pharmaceuticals (3) · Amgen (2) · Ampio Pharmaceuticals. Inc. (2) · Biosplice Therapeutics, Inc. (2) · Boehringer Ingelheim (2) · DePuy International (2) · Gilead Sciences (2) · Merck Sharp & Dohme LLC (2)
United States (57) · Poland (30) · Spain (25) · Canada (22) · Germany (22) · Russia (18) · Czechia (17) · United Kingdom (17) · Argentina (16) · France (16) · Australia (15) · Hungary (15) · South Korea (15) · Belgium (14) · Bulgaria (13)
Wolfgang Dummer, M.D. (3) · Barbara Hoggart, Dr. MD (1) · Benedikt Ostendorf, Prof.Dr. (1) · Bente Juel Riis, MD (1) · Brooks J Story, PhD (1)
PMID 30936738, PMID 24498318, PMID 26554876, PMID 37460782, PMID 23765873, PMID 30225992, PMID 36995469, PMID 10580823, PMID 16439323, PMID 18438931, PMID 18565256, PMID 19248105, PMID 20718590, PMID 20932224, PMID 21905001, PMID 22389919, PMID 23252526, PMID 23707270, PMID 23852695, PMID 24474088, PMID 24625625, PMID 25073573, PMID 25582279, PMID 25873635, PMID 26314396, PMID 26535134, PMID 28115015, PMID 28507219, PMID 29343266, PMID 29654485, PMID 30269054, PMID 31087226, PMID 31481084, PMID 31986264, PMID 32020029, PMID 32249039, PMID 32346093, PMID 33973384, PMID 34586472, PMID 34626502, PMID 37699654, PMID 40044198, PMID 41764561
2009 (6), 2019 (2), 2005 (1), 2008 (1), 2014 (1), 2015 (1), 2017 (1)